Кетопрофен: эффективный анальгетик с низким риском кардиоваскулярных осложнений


А.Е. Каратеев

Представлен обзор исследований, посвященных оценке действия нестероидных противовоспалительных средств (НВПС), применяемых с целью устранения хронических болевых синдромов при мышечно-скелетных заболеваниях. Основное внимание уделено традиционному (неселективному) НПВС кетопрофену, который появился в Европе в 1971 г. и быстро завоевал репутацию эффективного и надежного анальгетика. Кетопрофен – удобный и эффективный анальгетик, который может с успехом использоваться для как купирования острой, так и длительного контроля хронической боли. Благоприятные фармакологическое свойства этого препарата определяют его преимущества по сравнению с другими популярными НПВС.

Литература


1. Насонов Е.Л. Анальгетическая терапия в ревматологии: путешествие между Сциллой и Харибдой // Клин. фармакол. и терапия 2003. № 12(1). С. 64–9.
2. Боль (практическое руководство для врачей) / Под ред. Н.Н. Яхно, М.Л. Кукушкина. М., 2012. 512 c.
3. Lee Y. Effect and treatment of chronic pain in inflammatory arthritis. Curr Rheumatol Rep 2013;15(1):300.
4. van de Laar M, Pergolizzi J, Mellinghoff H, et al. Pain Treatment in Arthritis-Related Pain: Beyond NSAIDs. Open Rheumatol J2012;6:320–30.
5. Andersson H. Increased mortality among individuals with chronic widespread pain relates to
lifestyle factors: a prospective populationbased study. Disabil Rehabil 2009;31(24):1980–87.
6. Nuesch E, Dieppe P, Reichenbach S, et al. All cause and disease specific mortality in patients with knee or hip osteoarthritis: population based cohort study. BMJ 2011. 342:d1165. doi: 10.1136/bmj.d1165.
7. Tsuboi M, Hasegawa Y, Matsuyama Y, et al. Do musculoskeletal degenerative diseases affect mortality and cause of death after 10 years in Japan? J Bone Miner Metab 2011; 29(2):217–23.
8. Zhu K, Devine A, Dick I, Prince R. Association of back pain frequency with mortality, coronary heart events, mobility, and quality of life in elderly women. Spine 2007;32(18):2012–18.
9. Torrance N, Elliott A, Lee A, Smith B. Severe chronic pain is associated with increased 10 year mortality. A cohort record linkage study. Eur J Pain 2010;14(4):380–86.
10. Brennan F, Carr D, Cousins M. Pain management: a fundamental human right. Anesth Analg
2007;105:205–21.
11. Fishman S. Recognizing pain management as a human right: a first step. Int Anesth Res Soc 2007;105(1):8–9.
12. Arboleya L, de la Figuera E, Soledad Garcia M, Aragon B. Management pattern for patients with osteoarthritis treated with traditional nonsteroidal anti-inflammatory drugs in Spain prior
to introduction of Coxibs. Curr Med Res Opin 2003;19(4):278–87.
13. Gore M, Sadosky A, Leslie D, et al. Therapy Switching, Augmentation, and Discontinuation in Patients with Osteoarthritis and Chronic Low Back Pain. Pain Pract 2012;12(6):457–68.
14. McDougall J, Linton P. Neurophysiology of Arthritis Pain. Curr Pain Headache Rep 2012 Sep 29. [Epub ahead of print]
15. Schaible H. Mechanisms of chronic pain in osteoarthritis. Curr Rheumatol Rep 2012; 14(6):549–56.
16. Каратеев А.Е., Яхно Н.Н., Лазебник Л.Б.
и др. Применение нестероидных противовоспалительных препаратов.Клинические рекомендации. М., 2009. 167 с.
17. Lanas A, Garcia-Tell G, Armada B, Oteo-Alvaro A. Prescription patterns and appropriateness of
NSAID therapy according to gastrointestinal risk and cardiovascular history in patients with diagnoses
of osteoarthritis. BMC Medicine 2011, 9:38 doi:10.1186/1741-7015-9-38.
18. McGettigan P, Henry D. Cardiovascular risk with nonsteroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies. PLoS Med 2011; DOI:10.1371/journal.pmed.1001098.
19. Fosbol E, Folke F, Jacobsen S, et al. Cause-Specific Cardiovascular Risk Associated With Nonsteroidal Antiinflammatory Drugs Among Healthy Individuals Circ Cardiovasc Qual Outcomes 2010;3:395–405.
20. Veys E. 20 years’ experience with ketoprofen. Scand J Rheumatol Suppl1991;90(Suppl):1–44.
21. Sarzi-Puttini P, Atzeni F, Lanata L, et al. Pain and ketoprofen: what is its role in clinical practice?
Reumatismo 2010;62(3):172–88.
22. Venegoni M, Da Cas R, Menniti-Ippolito F, Traversa G. Effects of the European restrictive actions concerning nimesulide prescription: a simulation study on hepatopathies and gastrointestinal
bleedings in Italy. Ann Ist Super Sanita 2010;46(2):153–57.
23. Kokki H. Ketoprofen pharmacokinetics, efficacy, and tolerability in pediatric patients. Paediatr Drugs 2010;12(5):313–29.
24. Netter P, Lapicque F, Bannwarth B, et al. Diffusion of intramuscular ketoprofen into the cerebrospinal fluid. Eur J Clin Pharmacol 1985;29(3):319–21.
25. Herrero J, Parrado A, Cervero F. Central and peripheral actions of the NSAID ketoprofen on spinal cord nociceptive reflexes. Neuropharmacology 1997;36(10):1425–31.
26. Pehourcq F, Matoga M, Bannwarth B. Diffusion of arylpropionate non-steroidal anti-inflammatory drugs into the cerebrospinal fluid: a quantitative structure-activity relationship approach.Fundam Clin Pharmacol 2004;18(1):65–70.
27. Diaz-Reval M, Ventura-Martinez R, Deciga-Campos M, et al. Evidence for a central mechanism of action of S-(+)-ketoprofen. Eur JPharmacol 2004;483(2–3):241–48.
28. Mannila A, Kokki H, Heikkinen M, et al. Cerebrospinal fluid distribution of ketoprofen after intravenous administration in young children. Clin Pharmacokinet 2006;45(7):737–43.
29. http://www.vidal.ru/poisk_preparatov/ketonal-duo.htm
30. Barden J, Derry S, McQuay H, Moore R. Single dose oral ketoprofen and dexketoprofen for acute postoperative pain in adults. Cochrane Database Syst Rev 2009;(4):CD007355.
31. Glina S, Damiao R, Afif-Abdo J, et al. Efficacy and safety of parecoxib in the treatment of acute renal colic: a randomized clinical trial. Int Braz J Urol 2011;37(6):697–705.
32. Karvonen S, Salomaki T, Olkkola K. Efficacy of oral paracetamol and ketoprofen for pain management
after major orthopedic surgery. Methods Find Exp Clin Pharmacol 2008;30(9):703–06.
33. J Olson N, Otero A, Marrero I, et al. Onset of analgesia for liquigel ibuprofen 400 mg, acetaminophen
1000 mg, ketoprofen 25 mg, and placebo in the treatment of postoperative dental pain. Clin Pharmacol 2001;41(11):1238–47.
34. Dib M, Massiou H, Weber M, et al. Efficacy of oral ketoprofen in acute migraine: a double-
blind randomized clinical trial. Neurology 2002;58(11):1660–65.


35. Altman R, Honig S, Levin J, Lightfoot R. Ketoprofen versus indomethacin in patients with acute gouty arthritis: a multicenter, double blind comparative study. J Rheumatol 1988;15(9):1422–26.
36. Jokhio I, Siddiqui K, Waraich T, et al. Study of efficacy and tolerance of ketoprofen and diclofenac sodium in the treatment of acute rheumatic and traumatic conditions. J Pak Med Assoc 1998;48:373–76.
37. Le Loet X. Safety of ketoprofen in the elderly: a prospective study on 20,000 patients. Scand J
Rheumatol Suppl 1989;83:21–7.
38. Schattenkirchner M. Long-term safety of ketoprofen in an elderly population of arthritic patients. Scand J Rheumatol Suppl 1991;91:27–36.
39. Dougados M, Behier J, Jolchine I, et al. Efficacy of celecoxib, a cyclooxygenase 2-specific inhibitor,
in the treatment of ankylosing spondylitis:a six-week controlled study with comparison
against placebo and against a conventional nonsteroidal antiinflammatory drug. Arthritis Rheum 2001;44(1):180–85.
40. Atzeni F, Sarzi-Puttini P, Lanata L, Bagnasco M. Efficacy of Ketoprofen Vs Ibuprofen and Diclofenac: A Systematic Review of the Literature and Meta-Analysis. Arthritis Rheum 2012;64(10):114–15.
41. Henry D, Lim L, Garcia Rodriguez L, et al. Variability in risk of gastrointestinal complications
with individual non-steroidal anti-inflammatory drugs: results of a collaborative metaanalysis. BMJ 1996;312:1563–66.
42. Castellsague J, Riera-Guardia N, Calingaert B, et al. Individual NSAIDs and upper gastrointestinal
complications: a systematic review and metaanalysis of observational studies (the SOS project).
Drug Saf 2012;35(12):1127–46.
43. Helin-Salmivaara A, Saarelainen S, Gronroos J, et al. Risk of upper gastrointestinal events with
the use of various NSAIDs: A case-control study in a general population. Scan J Gastroenterol
2007;42:923–32.
44. Чичасова Н.В., Иммаметдинова Г.Р., Каратеев А.Е., и соавт. Эффективность и безопасность кетопрофена (кетонал) при ревматоидном артрите (клинико-эндоскопическое исследование) // Научно-практическая ревматология 2001. № 1. С. 47–52.
45. Осипова Н.А., Петрова В.В., Ермолаев П.М., Береснев В.А. Нестероидные противовоспалительные препараты в лечении послеоперационной боли у онкологических больных // Фарматека 2006. № 121.
46. Шмидт Е.И., Коган К.М., Белозерова И.В. Оценка эффективности кетонала ретард у больных остеоартрозом // Научно-практическая ревматология 2000. № 2.С. 77–9.
47. Новиков Г.А., Вайсман М.А., Прохоров Б.М. и др. Кетонал в лечении болевого синдрома у пациентов с распространенными формами злокачественных новообразований //Паллиативная медицина и реабилитация 2002. № 3. C. 48–51.
48. Лазебник Л.Б., Дроздов В.Н., Коломиец Е.В. Сравнительная эффективность и безопасность применения кетопрофена, лорноксикама, нимесулида и целекоксиба у больных остеоартрозом // РМЖ 2004.№ 12(14). С. 844–47.
49. Singh G, Mithal A, Triadafilopoulos G. Both selective COX-2 inhibitors and non-selective NSAIDs increase the risk of acute myocardial infarction in patients with arthritis; selectivity is with patients, not the drug. Ann Rheum Dis 2005;64(suppl 3):85.
50. Solomon D, Glynn R, Levin R, Avorn J.Nonsteroidal Anti-inflammatory Drug Use and Acute Myocardial Infarction. Arch Intern Med 2002;162:1099–104.
51. Helin-Salmivaara A, Virtanen A, Vesalainen R, et al. NSAID use and the risk of hospatalisation for first myocardial infarction in the general population: a national case-control study from Finland. Eur Heart J 2006;27:1657–63.
52. Altman R, Barthel H. Topical therapies for osteoarthritis. Drugs 2011;71(10):1259–79.
53. Massey T, Derry S, Moore R, McQuay H. Topical NSAIDs for acute pain in adults. Cochrane
Database Syst Rev 2010(6):CD007402.54. Kawai S, Uchida E, Kondo M, et al. Efficacy and safety of ketoprofen patch in patients with rheumatoid arthritis: a randomized, doubleblind, placebo-controlled study. J Clin Pharmacol 2010;50(10):1171–79.
55. Coaccioli S. Ketoprofen 2,5 % gel: a clinical overview. Eur Rev Med Pharmacol Sci 2011;15(8):943–49.
56. Komatsu T, Sakurada T. Comparison of the efficacy and skin permeability of topical NSAID
preparations used in Europe. Eur J Pharm Sci 2012;47(5):890–95.
57. Patel R, Leswell P. Comparison of ketoprofen, piroxicam, and diclofenac gels in the treatment
of acute soft-tissue injury in general practice. General Practice Study Group. Clin Ther 1996;18(3):497–507.
58. Esparza F, Cobian C, Jimenez J, et al. Topical ketoprofen TDS patch versus diclofenac gel: efficacy and tolerability in benign sport related soft-tissue injuries. Br J Sports Med 2007;41(3): 134–39.
59. Чичасова Н.В., Имаметдинова Г.Р. Кетонал крем в лечении поражения различных структур опорно-двигательного аппарата //РМЖ 2006. № 5. C. 414–18
60. Барскова В.Г. Современные аспекты применения гелей, содержащих кетопрофен при остеоартрозе // Справочник поликлинического врача 2008. № 11. C. 62–5.


Похожие статьи


Бионика Медиа